Press Release : Novartis Cosentyx receives FDA -2-

https://twitter.com/novartisnews https://twitter.com/novartisnews 
 
   For Novartis multimedia content, please visit 
https://www.novartis.com/news/media-library 
https://www.novartis.com/news/media-library 
 
   For questions about the site or required registration, please contact 
[e-mail] 
 
   References 
 
 
   1. Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis 
      Pharmaceuticals Corp; 2021. 
 
   2. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of 
      Dermatology-National Psoriasis Foundation guidelines of care for the 
      management and treatment of psoriasis in pediatric patients. J Am Acad 
      Dermatol. 2020;82(1):161-201. 
 
   3. Paller AS, Singh R, Cloutier M, et al. Prevalence of Psoriasis in 
      Children and Adolescents in the United States: A Claims-Based Analysis. J 
      Drugs Dermatol. 2018;17(2):187-194. 
 
   4. Data on file. Data Analysis Report: Study CAIN457A2302E1. Novartis 
      Pharmaceuticals Corp; November 30, 2015. 
 
   5. Data on file. CAIN457F2310 and CAIN457F2305 Summary of 5-Year Clinical 
      Safety in (Ankylosing Spondylitis). Novartis Pharmaceuticals Corp; May 
      2019. 
 
   6. Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals 
      Corp; November 2008. 
 
   7. Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. 
      Novartis Pharmaceuticals Corp; July 23, 2018. 
 
   8. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates 
      high sustained efficacy and a favourable safety profile in patients with 
      moderate--to--severe psoriasis through 5 years of treatment (SCULPTURE 
      Extension Study). J Eur Acad Dermatol Venerol. 2018;32(9):1507-1514. 
 
   9. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human 
      anti-interleukin-17A monoclonal antibody, in patients with psoriatic 
      arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, 
      phase 3 trial. Lancet. 2015;386(9999):1137-1146. 
 
  10. Marzo-Ortega H, Sieper J, Kivitz AJ, et al. 5-year efficacy and safety of 
      secukinumab in patients with ankylosing spondylitis: end-of-study results 
      from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2(6):E339-E346. 
 
  11. National Psoriasis Foundation. The impact of psoriasis. Available from: 
      https://www.psoriasis.org/psoriasis-statistics/. Accessed: May 26, 2021. 
 
  12. Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in 
      children: a population-based study. J Am Acad Dermatol. 
      2010;62(6):979-987. 
 
  13. Bronckers IMGJ, Paller AS, Van Geel MJ, et al. Psoriasis in Children and 
      Adolescents: Diagnosis, Management and Comorbilities. Paediatr Drugs. 
      2015;17:373-384. 
 
  14. Sieper J, Poddubnyy D and Miossec P. The IL-23-IL-17 pathway as a 
      therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 
      2019;15:747-757. 
 
  15. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained 
      Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 
      5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 
      2020;2:18-25. 
 
  16. Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting 
      interleukin-17. Br J Dermatol. 2012;167:717-24. 
 
  17. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with 
      psoriatic arthritis and axial manifestations: results from the 
      double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2020. 
 
  18. Novartis Europharm Limited. Cosentyx (secukinumab): Summary of Product 
      Characteristics. Available from: 
      https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf 
      [Last accessed: May 2021]. 
 
  19. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of 
      secukinumab 150 mg in ankylosing spondylitis: 5-year results from the 
      phase III MEASURE 1 extension study. RMD Open. 2019;5:e001005. 
 
  20. Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; October 
      2020. 
 
 
   # # # 
 
   Novartis Media Relations 
 
   E-mail: [e-mail] 
 
 
 
 
Michael Meo                               Louise Clark 
 Novartis Global External Communications   Novartis Pharma Communications 
 [phone] (direct)                  [phone] (direct) 
 [e-mail]                  [e-mail] 
 Julie Masow 
 Novartis US External Communications 
 [phone] 
 [e-mail] 
 
   Novartis Investor Relations 
 
   Central investor relations line: [phone] 
 
   E-mail: [e-mail] 
 
 
 
 
Central                                  North America 
Samir Shah              [phone]  Sloan Simpson  [phone] 
Thomas Hungerbuehler   [phone] 
 Isabella Zinck         [phone] 
 
 
 
 
 
 

(END) Dow Jones Newswires

June 01, 2021 16:30 ET (20:30 GMT)